News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
7,966 Results
Type
Article (1774)
Company Profile (2)
Press Release (6190)
Multimedia
Podcasts (17)
Webinars (1)
Section
Business (2445)
Career Advice (55)
Deals (516)
Drug Delivery (12)
Drug Development (1517)
Employer Resources (15)
FDA (282)
Job Trends (492)
News (4504)
Policy (498)
Tag
Academia (37)
Accelerated approval (1)
Adcomms (1)
Allergies (1)
Alliances (526)
ALS (6)
Alzheimer's disease (43)
Antibody-drug conjugate (ADC) (15)
Approvals (278)
Artificial intelligence (9)
Autoimmune disease (6)
Bankruptcy (2)
Best Places to Work (406)
BIOSECURE Act (1)
Biosimilars (43)
Biotechnology (1)
Brain cancer (1)
Cancer (108)
Cardiovascular disease (5)
Career advice (43)
Career pathing (1)
CAR-T (6)
CDC (1)
Cell therapy (23)
Clinical research (1277)
Collaboration (33)
Complete response letters (3)
COVID-19 (51)
C-suite (26)
Cystic fibrosis (3)
Data (101)
Denatured (3)
Depression (12)
Diabetes (4)
Diagnostics (38)
Diversity, equity & inclusion (3)
Drug discovery (10)
Drug pricing (24)
Drug shortages (2)
Duchenne muscular dystrophy (2)
Earnings (903)
Editorial (5)
Employer branding (7)
Employer resources (12)
Events (1143)
Executive appointments (24)
FDA (335)
Frontotemporal dementia (1)
Funding (23)
Gene editing (2)
Gene therapy (20)
GLP-1 (44)
Government (134)
Guidances (6)
Healthcare (130)
Huntington's disease (5)
IgA nephropathy (1)
Immunology and inflammation (30)
Indications (3)
Infectious disease (60)
Inflammatory bowel disease (15)
Inflation Reduction Act (1)
Interviews (6)
IPO (222)
IRA (6)
Job creations (86)
Job search strategy (41)
Labor market (5)
Layoffs (27)
Legal (133)
Longevity (1)
Lung cancer (5)
Lymphoma (45)
Management (2)
Manufacturing (17)
MASH (2)
Medical device (37)
Medtech (37)
Mergers & acquisitions (320)
Metabolic disorders (25)
Multiple sclerosis (2)
Neurodegenerative disease (21)
Neuropsychiatric disorders (9)
Neuroscience (104)
NextGen: Class of 2025 (106)
Non-profit (39)
Now hiring (42)
Obesity (18)
Opinion (17)
Ovarian cancer (8)
Pain (2)
Parkinson's disease (17)
Partnered (1)
Patents (13)
Patient recruitment (2)
People (892)
Pharmaceutical (1)
Pharmacy benefit managers (4)
Phase I (376)
Phase II (498)
Phase III (673)
Pipeline (71)
Policy (18)
Postmarket research (24)
Preclinical (89)
Prostate cancer (2)
Psychedelics (8)
Radiopharmaceuticals (1)
Rare diseases (15)
Real estate (53)
Recruiting (8)
Regulatory (356)
Reports (1)
Research institute (43)
Resumes & cover letters (5)
RNA editing (2)
RSV (6)
Schizophrenia (25)
Series A (9)
Series B (3)
Sickle cell disease (1)
Special edition (2)
Startups (65)
Supply chain (1)
Tariffs (12)
The Weekly (13)
Vaccines (12)
Venture capital (8)
Weight loss (16)
Worklife (1)
Date
Today (2)
Last 7 days (8)
Last 30 days (39)
Last 365 days (560)
2025 (554)
2024 (708)
2023 (610)
2022 (1063)
2021 (915)
2020 (764)
2019 (681)
2018 (550)
2017 (526)
2016 (501)
2015 (553)
2014 (325)
2013 (184)
2012 (29)
2011 (3)
Location
Africa (25)
Arizona (2)
Asia (418)
Australia (46)
California (194)
Canada (34)
China (8)
Colorado (3)
Connecticut (5)
Delaware (1)
Europe (1294)
Florida (8)
Georgia (5)
Illinois (113)
India (8)
Indiana (8)
Iowa (1)
Japan (8)
Maryland (6)
Massachusetts (119)
Michigan (1)
Minnesota (2)
Missouri (1)
Nebraska (1)
New Hampshire (1)
New Jersey (32)
New York (27)
North Carolina (7)
Northern California (55)
Ohio (4)
Oregon (1)
Pennsylvania (22)
Rhode Island (1)
South America (27)
South Carolina (1)
Southern California (117)
Tennessee (8)
Texas (8)
United States (526)
Utah (1)
Virginia (7)
Washington D.C. (5)
Washington State (4)
Wisconsin (2)
7,966 Results for "abbvie".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Layoffs
AbbVie Ends 11-Year Relationship With Calico, Lays Off 100+
In January, AbbVie and Calico’s fosigotifator failed to show significant signs of efficacy in the HEALEY ALS platform trial for amyotrophic lateral sclerosis.
November 13, 2025
·
2 min read
·
Tristan Manalac
Psychedelics
Psychedelics Space Enters New Era as AbbVie Dives In
With AbbVie’s $1.2 billion acquisition of Gilgamesh Pharmaceuticals’ lead depression drug, the psychedelic therapeutics space has soundly rebounded from Lykos’ rejection last year. There are now seven programs in Phase III trials across the sector, with multiple companies vying for that first approval.
September 22, 2025
·
6 min read
·
Heather McKenzie
Patents
AbbVie Adds Four Years of Exclusivity to Rinvoq Franchise With Generics Settlement
The settlement agreement will extend market exclusivity for AbbVie’s JAK inhibitor in the U.S. until 2037—providing pediatric exclusivity is granted.
September 12, 2025
·
2 min read
·
Tristan Manalac
Press Releases
OSE Immunotherapeutics Announces Strategic Amendment to AbbVie’s Partnership on ABBV-230 Development
December 8, 2025
·
5 min read
Earnings
AbbVie’s Immunology Dyad Dominates Again in Q3
Skyrizi and Rinvoq made nearly $7 billion combined, almost half of the company’s income for the quarter alone.
October 31, 2025
·
2 min read
·
Dan Samorodnitsky
Press Releases
AbbVie and adMare BioInnovations Foster Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award in Quebec
November 26, 2025
·
3 min read
Acquisitions
Unswayed by Cerevel Failure, AbbVie Buys Gilgamesh’s Depression Drug for $1.2B
The deal extends AbbVie’s commitment to the psychedelics space and depression, after emraclidine’s high-profile flop in schizophrenia last November.
August 25, 2025
·
3 min read
·
Annalee Armstrong
Lung Cancer
AbbVie’s ADC Nabs Accelerated Approval for Lung Cancer
AbbVie’s Emrelis is the first non-small cell lung cancer therapy approved for patients with high c-Met expression levels who have received prior lines of treatment.
May 15, 2025
·
2 min read
·
Tristan Manalac
Press Releases
AbbVie to Present at the Piper Sandler 37th Annual Healthcare Conference
November 24, 2025
·
1 min read
Press Releases
AbbVie Announces 20 Recipients of Migraine Career Catalyst Award™
November 14, 2025
·
4 min read
1 of 797
Next
